LH Labcorp Holdings Inc.

Danaher's Biotechnology segment posts 4% sales growth, but tough comparisons and shipment timing could test its momentum.

LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Labcorp Holdings (NYSE:LH) used its 2026 Investor Day to outline a push into targeted acquisitions and new lab technologies. Management emphasized capital deployment toward advanced lab management systems and expanded digital experiences for patients and providers. The company highlighted plans to integrate acquired platforms with its existing diagnostic infrastructure to streamline operations and data handling. Labcorp's renewed focus on acquisitions and digital lab tools only tells part of...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Labcorp Holdings stock has outpaced the Dow this year, and analysts remain bullish about its prospects.

The Dow Jones index fell on the stock market today after President Trump threatened Iran. Other major indexes rose. Apple was among stocks trading near buy points.

The government thinks it's been overpaying Labcorp. They plan to stop doing that next year.

Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers

Investing.com - U.S. stock index futures steadied on Tuesday, following a strong session on Wall Street that saw the benchmark S&P 500 post its best day since August, helped by gains in artificial intelligence-linked stocks.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Labcorp Holdings on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day. The health care company emphasized its innovation roadmap, technological advancements and solid financial expectations for the coming years. Reaffirming Financial Targets The...

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...

Do Wall Street analysts favor Labcorp’s stock, given its solid performance?

Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

LH's specialty-testing expansion, strategic partnerships and buybacks support growth, while reimbursement and cost pressures pose risks.

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.

Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.

Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.

Specialty testing and Central Labs fueled revenue growth and margin expansion.

DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.

Labcorp Holdings (NYSE:LH) has introduced the Marker by Labcorp Genetic Health Panel, a new consumer-focused genetic testing service. The product brings together genetic testing, counseling, and biomarker analysis in one offering for individuals looking to better understand their health risks. The launch uses Labcorp’s existing testing infrastructure alongside new AI-powered platforms to support more tailored insights for consumers. Investors watching Labcorp Holdings now have a fresh data...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $3.73 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.77 billion at the midpoint. Its non-GAAP profit of $4.99 per share was 4.6% above analysts’ consensus estimates.

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

Labcorp (NYSE:LH) reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance. Revenue rose 5.8% year over year to $3.7 billion, while adjusted operatin

Moby summary of Labcorp Holdings Inc.'s Q2 2026 earnings call

Specialty testing and Central Labs fueled revenue growth and margin expansion.

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

Labcorp Holdings Inc (LH) reports a 6% revenue increase to $3.7 billion and raises full-year 2026 guidance, driven by double-digit growth in specialty testing and robust Biopharma segment performance.

DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.

Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $3.73 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.77 billion at the midpoint. Its non-GAAP profit of $4.99 per share was 4.6% above analysts’ consensus estimates.

Labcorp (LH) delivered earnings and revenue surprises of +4.18% and +0.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?